Can-Fite Secures Eurasian Patent Allowance for Piclidenoson in Lowe Syndrome

PUBT · 2d ago
Can-Fite Secures Eurasian Patent Allowance for Piclidenoson in Lowe Syndrome
  • Can-Fite BioPharma received Eurasian patent allowance covering Piclidenoson for Lowe syndrome and Dent disease 2; grant remains subject to formalities.
  • Its agreement with patent owner Fondazione Telethon provides development, commercialization and out-licensing rights for these indications.
  • Preclinical studies demonstrated restoration of OCRL-dependent cellular function, supporting Piclidenoson's selection for clinical evaluation.
  • The open-label, single-center Phase 2 trial will evaluate twice-daily oral Piclidenoson for six months in five adults with genetically confirmed Lowe syndrome.
  • The primary endpoint measures renal uptake of 99mTc-DMSA to assess proximal tubular reabsorption; secondary endpoints assess tubular function and safety.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020700PRIMZONEFULLFEED9867891) on November 02, 2026, and is solely responsible for the information contained therein.